Clinical trials: Glaucoma,Open-Angle
Open Angle Glaucoma
Comparative Effectiveness and Safety of ELIOS in Patients With Open-Angle Glaucoma Undergoing Cataract Surgery
The primary study objective is to compare the effectiveness of the combination of phacoemulsification with intraocular lens implant with ELIOS or competitor device in reducing IOP at 12 months postoperatively.
- Trial name
- NCT06246136
- Testing
- ELIOS, Competitor Device
- Where
- 16 sites in Belgium, France and 4 more
- Volunteers
- 194 people
- Sponsor
- Elios Vision, Inc.
Open-Angle Glaucoma, Ocular Hypertension
Safety and Efficacy of Brinzolamide/Brimonidine Fixed Combination
The purpose of this study was to compare the safety and intraocular pressure (IOP)-lowering efficacy of a new fixed combination of brinzolamide/brimonidine (Brinz/Brim) to: its individual components (Brinz and Brim), and the…
- Trial name
- NCT00961649
- Testing
- Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide ophthalmic suspension, 1%, Brimonidine tartrate ophthalmic solution, 0.2%
- Volunteers
- 195 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle, Ocular Hypertension
Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
Phase IV randomized, double blind, multicenter, parallel group clinical study to evaluate the efficacy of the combined use of Krytantek Ofteno PF® and Gaap Ofteno PF®, both applied every 12 hours, versus the use of Eliptic Ofteno…
- Trial name
- PRO-122 (NCT04702789)
- Testing
- Dorzolamide-timolol-brimonidine and latanoprost, Dorzolamide-timolol and latanoprost
- Where
- Mexico
- Volunteers
- 28 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Glaucoma, Open-Angle, Ocular Hypertension
Phase 1-2 Evaluation of OT-730 Eye Drops in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-Angle Glaucoma
The purpose of this study is to evaluate the safety and potential efficacy of a new drug, OT-730 ophthalmic solution (eye drops), in reducing intraocular pressure in the eyes of patients with open angle glaucoma or ocular…
- Trial name
- NCT00753168
- Testing
- OT-730 ophthalmic solution, timolol maleate ophthalmic solution
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Othera Pharmaceuticals
Glaucoma, Open-Angle, Ocular Hypertension
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00051155
- Testing
- Travoprost (0.004%), Latanoprost (0.005%)/Timolol (0.5%)
- Where
- United States
- Sponsor
- Alcon Research
Glaucoma
Multi-Arm Feasibility Study Evaluating OTX-TP Compared to Timolol in Treatment of Subjects With Open Angle Glaucoma
The purpose of this study is to evaluate how OTX-TP, a sustained release travoprost drug product, when placed in the canaliculus of the eyelid compares to timolol drops for the lowering of intraocular pressure (IOP) in patients…
- Trial name
- NCT01845038
- Testing
- OTX-TPa ~4µg/day over 2 mos. with natural tears drops, OTX-TPb ~3µg/day over 3 months with natural tears drops, Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug
- Where
- South Africa
- Volunteers
- 41 people
- Sponsor
- Ocular Therapeutix, Inc.
Glaucoma, Glaucoma, Open Angle
SOLX Titanium Sapphire Laser for Trabeculoplasty
Use of the Titanium Sapphire laser for laser trabeculoplasty to reduce intraocular pressure in patients with poorly controlled intraocular pressure on maximally tolerated medical therapy or prior failed laser trabeculoplasty.
- Trial name
- NCT00145535
- Testing
- SOLX Titanium Sapphire Laser (TiSaLT), Argon Laser Trabeculoplasty (ALT)
- Where
- 10 sites in United States, Canada and 2 more
- Volunteers
- 120 people
- Sponsor
- SOLX, Inc.
Open Angle Glaucoma -Ocular Hypertension
28-Day Repeated Topical Study to Evaluate the Safety and Activity of 5 Escalating Dose Levels of SAR366234 and One Dose of Latanoprost in Patients With Open Angle Glaucoma or Ocular Hypertension
Primary Objective: To assess the local and systemic safety and tolerability of ascending repeated topical doses of SAR366234 monotherapy in patients with open angle glaucoma (OAG) or ocular hypertension (OHT) as compared to…
- Trial name
- NCT02531152
- Testing
- Latanoprost, SAR366234
- Where
- 5 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sanofi
Open-angle Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of the study is to evaluate the safety and effectiveness of an investigational therapy for treating patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00293787
- Testing
- Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution, Timolol Vehicle, Latanoprost 0.005% Ophthalmic Solution (XALATAN)
- Volunteers
- 156 people
- Sponsor
- Alcon Research
Glaucoma, Primary Open Angle, Ocular Hypertension
Evaluation of Safety and Efficacy of TUG (Therapeutic Ultrasound for Glaucoma) in the Treatment of Primary Open Angle Glaucoma or Ocular Hypertension
The purpose of this study is to evaluate whether the TUG device is safe and effective in patients with primary open angle glaucoma or ocular hypertension.
- Trial name
- NCT02858284
- Testing
- TUG
- Volunteers
- 25 people
- Sponsor
- EyeSonix
Ocular Hypertension, Open-Angle Glaucoma
The Effects of Preservative-free Prostaglandin Eye Drops in Sign and Symptoms on the Eyes of Patients With Glaucoma
The objective of this study is to investigate corneal confocal microscopic findings, ocular signs and symptoms in patients on treatment with the preserved prostaglandin analogue latanoprost 0.005% eye drops (Xalatan®) and after…
- Trial name
- NCT01369771
- Testing
- Tafluprost 0.0015%
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- FinnMedi Oy
Open-Angle Glaucoma, Ocular Hypertension
A Study of Simbrinza™ Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension
This study is a retrospective chart review to assess the tolerability and efficacy of treatment with Simbrinza™ used for patients with Open-Angle Glaucoma or Ocular Hypertension.
- Trial name
- NCT02348476
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
The objective of this clinical study is to evaluate the safety and efficacy of NCX 470 Ophthalmic Solution in lowering intraocular pressure (IOP) in subjecs with ocular hypertension or open-angle glaucoma.
- Trial name
- Denali (NCT04630808)
- Testing
- NCX 470 0.1%, Latanoprost 0.005%
- Where
- 88 sites in United States, China
- Volunteers
- 696 people
- Sponsor
- Nicox Ophthalmics, Inc.
Open-angle Glaucoma, Ocular Hypertension
24-hour IOP-lowering Effect of Brimonidine 0.1%
This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension
- Trial name
- NCT00457795
- Testing
- brimonidine 0.1% (Alphagan® P)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma
Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes
This clinical trial compares two implantable devices intended to lower the pressure inside the eye of glaucoma patients.
- Conditions
- Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma, Pigmentary Glaucoma
- Trial name
- COMPARE (NCT02023242)
- Testing
- Hydrus Microstent, iStent Trabecular Micro Bypass
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Ivantis, Inc.
Healthy Volunteers
Bimatoprost Ocular Insert Pharmacokinetic Study
The Bimatoprost Ocular Insert is intended to provide sustained delivery of bimatoprost to the ocular surface to lower the intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT02444767
- Testing
- 13mg Bimatoprost Ocular Insert
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- ForSight Vision5, Inc.
Hypertension, Glaucoma, Open-Angle
A Study of RO5093151 in Patients With Ocular Hypertension Or Open Angle Glaucoma
This randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and the effect of RO5093151 on intraocular pressure in patients with ocular hypertension or open angle glaucoma.
- Trial name
- NCT01493271
- Testing
- RO5093151
- Where
- 12 sites in United States, Bulgaria and 2 more
- Volunteers
- 31 people
- Sponsor
- Hoffmann-La Roche
Open-angle Glaucoma, Ocular Hypertension
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients
The purpose of this study is to determine the safety and IOP-lowering ability of a glaucoma therapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00069706
- Testing
- AL-12182 0.003% Ophthalmic Solution, AL-12182 Ophthalmic Solution Vehicle, Latanoprost 0.005% Ophthalmic Solution
- Volunteers
- 118 people
- Sponsor
- Alcon Research
Glaucoma, Open-Angle
A Prospective Evaluation of Glaucoma Subjects Treated With Two Second Generation iStents and One iStent Supra
Prospective Evaluation of Open-Angle Glaucoma Subjects treated with two second generation iStents and one iStent Supra
- Trial name
- GCF-041 (NCT03255798)
- Testing
- G2 and G3
- Where
- Germany
- Volunteers
- 7 people
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma
Study of OMNI System in OAG (GEMINI)
This study will prospectively assess the clinical effect of ab-interno transluminal viscoelastic delivery and trabeculotomy performed using the OMNI Surgical System in combination with Cataract Extraction on intraocular pressure…
- Trial name
- NCT03861169
- Testing
- Transluminal viscoelastic delivery and trabeculotomy
- Where
- 15 sites in United States
- Volunteers
- 209 people
- Sponsor
- Sight Sciences, Inc.